KRONİK LENFOSİTİK LÖSEMİ (KLL) TEDAVİSİ

Kaynaklar:

1- Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov. 167 (4):466-77. 

2- Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010 Sep 1. 16(17):4331-8. 

3-Nelson R. FDA Grants Full Approval to Ofatumumab (Arzerra) for CLL. Medscape Medical News. Accessed: March 10, 2016.

4-Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13. 370(11):997-1007. 

5-van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct. 16 (13):1370-9. 

6-Robak, T, Warzocha, K, Babu, KG, et al. Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial. Blood. 2015. 126(23):5288. 

7-Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20. 370 (12):1101-10. 

8-McCall B. Obinutuzumab Active in Elderly Chronic Lymphocytic Leukemia. Medscape Medical News from the 18th Congress of the European Hematology Association (EHA). June 21, 2013; Accessed: October 21, 2019.

9-Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Dec 6. 132 (23):2446-2455. 

10-Mougalian SS, O'Brien S. Adverse prognostic features in chronic lymphocytic leukemia. Oncology (Williston Park). 2011 Jul. 25(8):692-6, 699. 

11-Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, et al. Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. J Clin Oncol. 2011 Apr 1. 29(10):1349-55. 

12-Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2. 376(9747):1164-74. 

13-Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4. 369(1):32-42. 

14-Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17. 371 (3):213-23. 

15-Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17. 373 (25):2425-37. 

16-Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation. Blood. 2019 Oct 3. 118 (8):2062-8. 

17-Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019 Oct 1. 74 (13):1667-1678. 

18-Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020 Jul 30. 383 (5):460-473. 

19-Puła B, Gołos A, Górniak P, Jamroziak K. Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers (Basel). 2019 Nov 21. 11 (12):

20-Project Orbis: FDA approves acalabrutinib for CLL and SLL. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. November 21, 2019; Accessed: June 3, 2020.

21-Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022 Jan 1. 

22-Chustecka Z. Idelalisib (Zydelig) approved for CLL and lymphoma. Medscape Medical News. July 23, 2014. 

23-FDA news release: FDA approves Zydelig for three types of blood cancers. US Food and Drug Administration. July 23, 2014. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm.

24-Venclexta (venetoclax) [package insert]. North Chicago, IL: AbbVie, Inc. May 2019. Available at 

25-González-Rodríguez AP, Payer AR, Acebes-Huerta A, Huergo-Zapico L, Villa-Alvarez M, Gonzalez-García E, et al. Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int. 2013. 2013:932010. 

26-FDA approves venetoclax for CLL and SLL. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll. May 15, 2019; Accessed: September 13, 2019.

27-Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 May 30. 380 (22):2095-2103. 

29-Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22. 378 (12):1107-1120. 

30-Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 Feb 1. 37 (4):269-277. 

31-Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May. 94 (S1):S3-S9. 

32-Melville NA. CLL Patients 'Cured': 10 Years Post-Infusion, CAR T Cells Persist. Medscape Medical News. February 3, 2022; Accessed: February 7, 2022.

33-Laurenti L, Innocenti I, Autore F, et al. Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica. 2017 Sep. 102 (9):e352-e355. 

34-Gribben JG, Hosing C, Maloney DG. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2011 Jan. 17(1 Suppl):S63-70. 

35-Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011 May. 96(5):752-61. 

36-Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009 May. 50(5):764-72. 

37-Shanafelt T, Lanasa MC, Call TG, et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013 Aug 6. 

38-Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol. 2019 Jul 11. JCO1900894.